The role of titanium dioxide (E171) and the requirements for replacement materials in oral solid dosage forms: An IQ Consortium Working Group Review
An important paper has been recently published in the Journal of Pharmaceutical Sciences (JPharmSci) by the IQ Consortium that addresses the benefits of using TiO2 in pharmaceutical applications and the challenges that exist with trying to use the various TiO2 alternatives that currently exist.
ABSTRACT: Titanium dioxide (in the form of E171) is a ubiquitous excipient in tablets and capsules for oral use. In the coating of a tablet or in the shell of a capsule the material disperses visible and UV light so that the contents are protected from the effects of light, and the patient or caregiver cannot see the contents within. It facilitates elegant methods of identification for oral solid dosage forms, thus aiding in the battle against counterfeit products. Titanium dioxide ensures homogeneity of appearance from batch to batch fostering patient confidence. The ability of commercial titanium dioxide to disperse light is a function of the natural properties of the anatase polymorph of titanium dioxide, and the manufacturing processes used to produce the material utilized in pharmaceuticals. In some jurisdictions E171 is being considered for removal from pharmaceutical products, as a consequence of it being delisted as an approved colorant for foods. At the time of writing, in the view of the authors, no system or material which could address both current and future toxicological concerns, of Regulators and the functional needs of the pharmaceutical industry and patients, has been identified. This takes into account the assessment of materials such as calcium carbonate, talc, isomalt, starch and calcium phosphates. In this paper an IQ Consortium team outlines the properties of titanium dioxide and criteria to which new replacement materials should be held.
You can access the full paper for FREE at the following link: The Role of Titanium Dioxide (E171) and the Requirements for Replacement Materials in Oral Solid Dosage Forms: An IQ Consortium Working Group Review - ScienceDirect